TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9231947
Drug: Org 10172
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 10172 (1250 anti‐Xa Units s.c. once daily)
Study: 9231947
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium (5000 IU s.c. twice daily)
Study: 2493376
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus intravenous gammaglobulin (i.v. IgG)
Study: 2493376
Drug: Antibiotics (cefataxim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (cefataxim and amikacin)
Study: 29132440
Drug: Immediate, intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate, intensive periodontal treatment (n=30)
Study: 29132440
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (n=30)
Study: 26016052
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy and CPAP (Group B)
Study: 26016052
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy only (Group A)
Study: 23131570
Drug: Sea buckthorn
Normalized name: sea buckthorn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sea buckthorn oil (SBO) extract, 4 capsules per day, each containing 500 mg, for 8 weeks
Study: 23131570
Drug: Placebo, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 4 capsules per day for 8 weeks
Study: 22283033
Drug: Zinc (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (5 mg), Iron (6.25 mg), Folic Acid (25 microg) supplementation
Study: 22283033
Drug: Combined micronutrient
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined micronutrient supplements (Zinc, Iron, Folic Acid)
Study: 20128376
Drug: monotherapy (amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: monotherapy (amlodipine 5 mg or valsartan 80 mg)
Study: 16401691
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg for three weeks, 40 mg for three weeks)
Study: 10894590
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of combination therapy
Study: 10894590
Drug: 48 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 weeks of combination therapy
Study: 9004394
Drug: Treatment effect
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effect estimate under covariate omission or categorization
Study: 27867020
Drug: PO baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO baclofen 20 mg
Study: 27867020
Drug: IV baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV baclofen 15 mg
Study: 27867020
Drug: PO baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO baclofen (10 mg, 15 mg, 20 mg)
Study: 27867020
Drug: IV baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV baclofen (7.5 mg, 11.5 mg, 15 mg)
Study: 23345946
Drug: Partially hydrolyzed
Normalized name: Human Skin Proteins, Partially Hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolyzed guar gum (PHGG) at dosage of 5 g/d (n = 30)
Study: 19299778
Drug: Oral 5
Normalized name: Syringe Oral 5cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5 mg melatonin
Study: 14504664
Drug: Bambuterol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol (10 mg tablets twice daily)
Study: 14504664
Drug: Terbutaline (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (7.5 mg controlled release tablets twice daily)
Study: 14504664
Drug: Intravenous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous terbutaline (injected intradermally)
Study: 10490735
Drug: Pneumococcal polysaccharide
Normalized name: pneumococcal polysaccharides (23)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal polysaccharide (Pnc PS) vaccine
Study: 10490735
Drug: Hib-diphtheria toxoid
Normalized name: DIPHTHERIA TOXOID
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib-diphtheria toxoid conjugate vaccine (PRP-D)
Study: 31211448
Drug: BIIB054 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB054 (15 or 45 mg/kg)
Study: 13678427
Drug: Irbesartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (angiotensin II type I receptor antagonist)
Study: 13678427
Drug: Atenolol (beta1‐adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta1‐adrenoceptor blocker)
Study: 11045833
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of antacid and anti-ulcer drugs during the last month of pregnancy by mothers
Study: 11045833
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of antacid and anti-ulcer treatments
Study: 1827006
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg isradipine twice daily
Study: 1533528
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg diltiazem thrice daily
Study: 24121915
Drug: Betamethasone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (12 mg)
Study: 6691394
Drug: Hydrocortisone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (250 mg)
Study: 6691394
Drug: Methylprednisolone (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (125 mg)
Study: 26982815
Drug: Tirasemtiv (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirasemtiv (125 mg b.i.d. for one week, then escalating to a maximum tolerated dose up to 250 mg b.i.d.)
Study: 24786192
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation with high water activity
Study: 24786192
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation with urea
Study: 24786192
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation with glycerol
Study: 24786192
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation with low water activity
Study: 21194471
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein meal replacement (HP) providing 2.2 g protein/kg of lean body mass (LBM)/day
Study: 21194471
Drug: Standard protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protein meal replacement (SP) providing 1.1 g protein/kg LBM/day
Study: 17478542
Drug: Indian HB
Normalized name: Indian frankincense
DrugBank: Indian frankincense (DB14275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indian HB vaccine (GeneVac‐B)
Study: 17478542
Drug: European HB
Approvals — FDA: no, EMA: no, PMDA: no
Description: European HB vaccine (Engerix‐B)
Study: 2844467
Drug: S‐9780 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐9780 (1 mg administered intravenously)
Study: 2844467
Drug: Perindopril (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (8 mg administered orally)
Study: 21177013
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (n = 39)
Study: 18326602
Drug: CARB-L (lunch
Approvals — FDA: no, EMA: no, PMDA: no
Description: CARB-L (lunch intervention)
Study: 16549962
Drug: Lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine monotherapy (300 mg once daily)
Study: 16549962
Drug: Complete therapy
Normalized name: Monistat 7 Complete Therapy Combination Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete therapy interruption (TI group)
Study: 7711339
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg
Study: 17917321
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg
Study: 10619580
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg vs 16 mg
Study: 1777373
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of dermatan sulphate (100 and 300 mg)
Study: 1777373
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of dermatan sulphate (1 g)
Study: 7028071
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate preceded 10 minutes earlier by inhalation of salbutamol
Study: 7028071
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate followed 10 minutes later by salbutamol
Study: 22410469
Drug: Wedge supine
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wedge supine position immediately after spinal injection (group S)
Study: 6754416
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal spray (200 micrograms and 400 micrograms per day)
Study: 28937065
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (i.v. CyP)
Study: 24621999
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg twice a day
Study: 21355150
Drug: Acupoint-catgut-embedding therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint-catgut-embedding therapy combined with conventional western medication
Study: 25233647
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medication
Study: 7658972
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO) administered at 25 U/kg/dose, i.v. route, three times weekly, adjusted according to hematimetric response.
Study: 7658972
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO) treatment.
Study: 3300135
Drug: PGE2 gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 gel, 0.5 mg (2.5 ml)
Study: 3300135
Drug: Non-gel control
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-gel control
Study: 25449207
Drug: Alkaline phosphatase
Normalized name: Alkaline phosphatase
DrugBank: Alkaline Phosphatase (DB05768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkaline phosphatase ≤143 U/l
Study: 25449207
Drug: Bone-specific alkaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-specific alkaline phosphatase (BSAP) <146 U/l
Study: 25449207
Drug: Prostate-specific antigen
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate-specific antigen (PSA) level <10 ng/ml
Study: 25449207
Drug: Hemoglobin >128g/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin >128g/l
Study: 22759078
Drug: OZ439 (200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZ439 (200-800 mg/day for 3 days as oral dispersion)
Study: 21724705
Drug: CH-1504 (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CH-1504 (0.25 mg, 0.5 mg, or 1.0 mg once-daily oral doses)
Study: 21724705
Drug: MTX (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX (titrated to 20.0 mg once-weekly oral doses)
Study: 12673721
Drug: Isoprinosine (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprinosine (adjuvant treatment)
Study: 10903017
Drug: Esmolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (15 mg/min) added to cold blood cardioplegia
Study: 9021698
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow transplantation (ABMT) after high dose therapy
Study: 28985286
Drug: Organizational-support strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organizational-support strategies (e.g. manager support, emails) with activity tracker
Study: 28985286
Drug: Organizational-support strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organizational-support strategies (e.g. manager support, emails) without activity tracker
Study: 24315492
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection + thumb spica cast (CSI + TSC)
Study: 23494116
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (CSI)
Study: 15807879
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy for 6 months
Study: 15994622
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive (25-mug daily dose of ethinyl estradiol)
Study: 15994622
Drug: Contraceptive vaginal
Normalized name: VCF 4% Contraceptive Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive vaginal ring (15-mug daily dose of ethinyl estradiol)
Study: 6217028
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive
Study: 12622108
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (group B) using propofol and remifentanil infusions
Study: 2423788
Drug: Indoramin 25
Normalized name: indoramin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin 25 mg three times daily
Study: 2423788
Drug: Indoramin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin 0.2 mg/kg i.v.
Study: 30546229
Drug: Experimental A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental A group (conventional, noninvasive treatment with raj‐yoga meditation therapy and pranayama)
Study: 30546229
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional, noninvasive treatment)
Study: 30546229
Drug: Experimental B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental B group (Raj‐yoga meditation therapy and pranayama only)
Study: 27715335
Drug: Salmeterol/Fluticasone (SFC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/Fluticasone (SFC) 50/500 μg twice daily
Study: 9589819
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 0.1% ointment
Study: 1103916
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration into the vastus lateralis muscle of diazepam 10 mg
Study: 31577085
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g intravenous vitamin C
Study: 31577085
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aceclofenac
Study: 17990218
Drug: Single carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single carbohydrate feeding (SF) - 2.5 g carbohydrate per kg body mass, 3 hours before exercise
Study: 9301390
Drug: Intradermal testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal testing
Study: 7957157
Drug: Large contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large contact material mass (3559 g)
Study: 1297939
Drug: Midazolam 15
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 15 mg once daily for seven days
Study: 6925461
Drug: C 1821,
Approvals — FDA: no, EMA: no, PMDA: no
Description: C 1821, administered orally for 14 days
Study: 6925461
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered orally for 14 days
Study: 29436087
Drug: Multidirectional reach
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidirectional reach training combined with conventional physical therapy (30 min each, 3 days a week for 4 weeks)
Study: 29436087
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (30 min per day, 3 days a week for 4 weeks)
Study: 24012203
Drug: Continuous norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous norepinephrine administration starting with 2 μg/kg per hour combined with 1 ml/kg per hour of Ringer's maleate solution until bladder removal, then 3 ml/kg per hour of Ringer's maleate solution (norepinephrine/low‐volume group)
Study: 24012203
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving 6 ml/kg per hour of Ringer's maleate solution throughout surgery
Study: 21660978
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg danoprevir solution delivered to the distal small bowel and colon via an Enterion™ capsule
Study: 16532880
Drug: Specialty approach
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specialty approach (medication restricted to smoking cessation clinics)
Study: 15567788
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol combined with fentanyl (group B)
Study: 10786107
Drug: Subcutaneous suture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous suture (group 1)
Study: 10786107
Drug: No subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No subcutaneous suture (group 2)
Study: 9378168
Drug: Carboplatin (C)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (C) 400 mg/m2 every three weeks
Study: 9378168
Drug: Carboplatin 350
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 350 mg/m2, ifosfamide (I) 5 g/m2 with mesna, vincristine (V) 1.4 mg/m2, and bleomycin (B) 30 mg every ten days (CIVB arm)
Study: 8638801
Drug: Vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.1 mg/kg
Study: 3475430
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (hydrochlorothiazide + triamterene) with methyldopa if blood pressure remained elevated
Study: 18604321
Drug: Standard nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nutritional supplement
Study: 6639916
Drug: Both supplements
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both supplements
Study: 31538149
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% prior to 0.5 mg/kg midazolam (group B)
Study: 31538149
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg midazolam (group A)
Study: 31538149
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% (placebo) with 0.5 mg/kg midazolam (group C)
Study: 27696490
Drug: Propofol (high,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (high, 3 μg/mL; medium, 1.5 μg/mL; low, 0.5 μg/mL; or no drug) and Remifentanil (high, 6 or 8 ng/mL; medium, 4 ng/mL; low, 2 ng/mL; or no drug)
Study: 19673337
Drug: Chemotherapy (FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (FOLFOX regimen) combined with Shenqi Fuzheng Injection (SFI)
Study: 19673337
Drug: Chemotherapy (FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (FOLFOX regimen) alone
Study: 10920901
Drug: ProMACE‐CytaBOM (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProMACE‐CytaBOM (treatment group)
Study: 29729655
Drug: Sexual risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sexual risk reduction intervention (details on dosage and duration not available)
Study: 25041811
Drug: ABT-384 single-dose
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-384 single-dose (1, 8, 20, 50, 120 and 240 mg)
Study: 22951426
Drug: Oral cefditoren
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cefditoren pivoxil 400mg once daily
Study: 18028385
Drug: Combined spinal-epidural
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spinal-epidural analgesia with subarachnoid morphine, bupivacaine, and fentanyl (MBF group)
Study: 18028385
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and bupivacaine (MB group)
Study: 18028385
Drug: Morphine (M
Normalized name: Product containing morphine (medicinal product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (M group)
Study: 10685817
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTX‐A) 100 units diluted in 1 ml saline, injected at five trigger points (0.2 ml each) via a 30 gauge needle.
Study: 10685817
Drug: Saline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (1 ml) as placebo control, injected at five trigger points.
Study: 18355366
Drug: Low-dose HT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose HT (1 mg 17 beta‐estradiol + 0.5 mg norethisterone acetate)
Study: 18355366
Drug: Conventional-dose HT
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose HT (2 mg 17 beta‐estradiol and 1 mg NETA)
Study: 17156824
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg)
Study: 12767572
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen replacement therapy (TTS 50 twice‐weekly)